SeaStar Medical's 2025 Revenue Surges to $1.2M, Annual Loss Narrows to $12.2M on Strong Product Adoption
ICU is trading near its 52-week low of $2.07 (11% above the low).
Summary
SeaStar Medical reported a substantial improvement in its full-year 2025 financial performance, with net revenue surging to $1.234 million, a significant increase from $135 thousand in 2024. Concurrently, the company successfully narrowed its annual net loss to $12.2 million, down from $24.8 million in the prior year. This positive financial trend is supported by strong operational progress, including the expansion of QUELIMMUNE's commercial adoption to 16 pediatric centers and the completion of enrollment for its FDA-mandated SAVE Registry. Additionally, the NEUTRALIZE-AKI adult pivotal trial has surpassed 50% enrollment, and a new cardio-renal trial (NEUTRALIZE-CRS) has been initiated with Breakthrough Device Designation. These developments are highly material for the small medical device company, signaling progress in both commercialization and pipeline advancement, and could positively impact investor sentiment. Traders will monitor continued clinical trial progress and further commercial traction.
At the time of this announcement, ICU was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $2.07 to $25.70. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.